睿昂基因(688217) - 2025 Q2 - 季度财报

Important Notice This section provides critical information regarding the company's semi-annual report, including statements from governance bodies, risk warnings, and key financial decisions Statement by Board of Directors, Supervisory Board, and Senior Management The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content, assuming corresponding legal liabilities. The company's head, chief accountant, and head of accounting department declare the financial report is true, accurate, and complete - The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content[3] - Company head Gao Shangxian, chief accountant Wang Chunjuan, and head of accounting department Wang Chunjuan declare the financial report is true, accurate, and complete[6] Significant Risk Warning The company has detailed potential risks in the report, advising investors to refer to "Section III Management Discussion and Analysis" under "IV. Risk Factors" and be aware of investment risks - The company has described potential risks in this report; please refer to "Section III Management Discussion and Analysis" under "IV. Risk Factors"[4] Absence of Directors Chairman Xiong Hui was unable to personally attend the board meeting due to arrest and has entrusted Gao Shangxian to attend on her behalf Absence of Directors | Position of Absent Director | Name of Absent Director | Reason for Absence | Name of Proxy | | :--- | :--- | :--- | :--- | | Chairman | Xiong Hui | Unable to personally attend due to arrest | Gao Shangxian | Audit Status This semi-annual report is unaudited - This semi-annual report is unaudited[6] Profit Distribution Plan The company proposes to distribute a cash dividend of RMB 1.70 (tax inclusive) per 10 shares to all shareholders based on the total share capital on the equity registration date for the 2025 semi-annual profit distribution, with no capital reserve conversion or bonus shares. This plan is subject to shareholder approval - The company proposes to distribute a cash dividend of RMB 1.70 (tax inclusive) per 10 shares to all shareholders based on the total share capital registered on the equity registration date for the 2025 semi-annual profit distribution, with no capital reserve conversion or bonus shares[7] 2025 Semi-Annual Profit Distribution Plan | Indicator | Amount/Quantity | | :--- | :--- | | Cash Dividend per 10 Shares (incl. tax) | 1.70 RMB | | Total Share Capital (as of June 30, 2025) | 55,855,896 shares | | Number of Shares Participating in Profit Distribution | 55,186,275 shares | | Total Proposed Cash Dividend (incl. tax) | 9,381,666.75 RMB | Forward-Looking Statement Risk Disclaimer Forward-looking statements in this report regarding the company's future plans and development strategies do not constitute substantive commitments, and investors are advised to be aware of investment risks - Forward-looking statements in this report regarding the company's future plans and development strategies do not constitute substantive commitments to investors, and investors are advised to be aware of investment risks[9] Section I Definitions This section provides definitions of common terms used in the report, covering professional terminology to ensure accurate understanding Definitions of Common Terms This section provides definitions of common terms used in the report, covering professional terminology such as company names, subsidiaries, shareholders, in vitro diagnostic (IVD) related technologies (e.g., molecular diagnostics, immunodiagnostics, PCR, gene sequencing, FISH, ddPCR), and medical device registration classifications, ensuring accurate understanding of the report - Definitions of common terms in the report, including company, subsidiaries, shareholders, in vitro diagnostics (IVD) and its classifications, molecular diagnostics, immunodiagnostics, PCR, gene sequencing, FISH, ddPCR, and other professional terminology[14][15] Section II Company Profile and Key Financial Indicators This section provides an overview of the company's basic information, contact details, stock profile, and key financial performance metrics Company Basic Information Shanghai Rightongene Biomedical Technology Co., Ltd. (Rightongene) was listed on the STAR Market of the Shanghai Stock Exchange on May 17, 2021, with Xiong Hui as its legal representative, and its registered and office addresses located in Fengxian District, Shanghai Company Basic Information | Indicator | Content | | :--- | :--- | | Chinese Name | 上海睿昂基因科技股份有限公司 | | Chinese Abbreviation | 睿昂基因 | | Legal Representative | Xiong Hui | | Registered Address | Building 3, No. 6055 Jinhai Highway, Fengxian District, Shanghai | | Office Address | No. 147, Lane 1817, Huifeng West Road, Fengxian District, Shanghai | | Company Website | www.rightongene.com | Contact Person and Information The company's Board Secretary (domestic representative for information disclosure) is Zhou Haihong, and the Securities Affairs Representative is Ju Kuo; contact addresses and email addresses have been disclosed Contact Person and Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary (domestic representative for information disclosure) | Zhou Haihong | No. 147, Lane 1817, Huifeng West Road, Fengxian District, Shanghai | 021-33282601 | 021-37199015 | zqswb@rightongene.com | | Securities Affairs Representative | Ju Kuo | No. 147, Lane 1817, Huifeng West Road, Fengxian District, Shanghai | 021-33282601 | 021-37199015 | zqswb@rightongene.com | Information Disclosure and Document Availability The company designates Shanghai Securities News, Securities Times, Securities Daily, and China Securities Journal as its information disclosure newspapers, with the semi-annual report published on the Shanghai Stock Exchange website and available at the company's Board of Directors Office - The company's selected information disclosure newspapers are Shanghai Securities News, Securities Times, Securities Daily, and China Securities Journal[19] - The website address for the semi-annual report is http://www.sse.com.cn/[19](index=19&type=chunk) - The company's semi-annual report is available at the company's Board of Directors Office[19] [Company Stock Overview](index=7&type=section&id=%E5%85%AC%E5%8F%B8%